Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study

Figure 2

Overall survival of RNOP-09 patients as compared to historical control. Kaplan-Meier estimates of overall survival according to treatment group. The unadjusted hazard ratio for death among patients treated with PEG-Dox and prolonged administration of TMZ as compared with those treated in the EORTC26981/NCIC-CE.3 trial was 0.83 (CI: 0.60-1.16; p = 0.28).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us